Loading
A phase 2 trial of Naporafenib, Trametinib, Ribociclib in melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT04417621 by Novartis Pharmaceuticals, with 134 participants enrolled, started 2020-10-30 and due to reach its primary completion in 2027-02-02. Interventions recorded: LXH254, LTT462, Trametinib, Ribociclib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Naporafenib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Ribociclib, Trametinib, Novartis.
Shares Trametinib, BRAF V600-mutant melanoma, Advanced melanoma (unresectable stage III and stage IV).
Shares Trametinib, BRAF V600-mutant melanoma.
Shares Ribociclib, Novartis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/